Evidence map›Paper›PMID 32918177›Full record

ArticleAnnals of surgical oncology2020

Oncologic Outcomes After Isolated Limb Infusion for Advanced Melanoma: An International Comparison of the Procedure and Outcomes Between the United States and Australia.

Michael J Carr, James Sun, Hidde M Kroon, John T Miura, Georgia M Beasley, Norma E Farrow, Paul J Mosca, Michael C Lowe, Clara R Farley, Youngchul Kim and 15 more

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Annals of surgical oncology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
0.5field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 11 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Review
  5. The Diagnosis and Management of Cutaneous Metastases from Melanoma.International journal of molecular sciences · 2023
    Review
  6. Management of In-Transit Metastases.Current oncology reports · 2022
    Review
  7. Review
  8. Article
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

25 authors at 12 institutions in 2 countries.

Michael J CarrDepartment of Cutaneous Oncology, Moffitt Cancer Center and Research Institute, Tampa, FL, USA.ORCID http://orcid.org/0000-0001-6233-4004
James SunDepartment of Cutaneous Oncology, Moffitt Cancer Center and Research Institute, Tampa, FL, USA.
Hidde M KroonDepartment of Surgery, Royal Adelaide Hospital, University of Adelaide, Adelaide, SA, Australia.
John T MiuraDepartment of Cutaneous Oncology, Moffitt Cancer Center and Research Institute, Tampa, FL, USA.
Georgia M BeasleyDepartment of Surgery, Duke University, Durham, NC, USA.
Norma E FarrowDepartment of Surgery, Duke University, Durham, NC, USA.
Paul J MoscaDepartment of Surgery, Duke University, Durham, NC, USA.
Michael C LoweDivision of Surgical Oncology, Department of Surgery, Winship Cancer Institute, Emory University, Atlanta, GA, USA.
Clara R FarleyDivision of Surgical Oncology, Department of Surgery, Winship Cancer Institute, Emory University, Atlanta, GA, USA.
Youngchul KimDepartment of Biostatistics and Bioinformatics, Moffitt Cancer Center and Research Institute, Tampa, FL, USA.
Syeda Mahrukh Hussnain NaqviDepartment of Biostatistics and Bioinformatics, Moffitt Cancer Center and Research Institute, Tampa, FL, USA.
Dennis A KirichenkoUniversity of South Florida Morsani College of Medicine, University of South Florida, Tampa, FL, USA.
Aishwarya PotdarUniversity of South Florida Morsani College of Medicine, University of South Florida, Tampa, FL, USA.
Hala DaouUniversity of South Florida Morsani College of Medicine, University of South Florida, Tampa, FL, USA.
Dean MullenDepartment of Surgery, Royal Adelaide Hospital, University of Adelaide, Adelaide, SA, Australia.
Jeffrey M FarmaDepartment of Surgical Oncology, Fox Chase Cancer Center, Philadelphia, PA, USA.
Michael A HendersonDivision of Surgical Oncology, Peter MacCallum Cancer Centre, University of Melbourne, Melbourne, VIC, Australia.
David SpeakmanDivision of Surgical Oncology, Peter MacCallum Cancer Centre, University of Melbourne, Melbourne, VIC, Australia.
Jonathan SerpellDiscipline of Surgery, The Alfred Hospital, Melbourne, VIC, Australia.
Keith A DelmanDepartment of Biostatistics and Bioinformatics, Moffitt Cancer Center and Research Institute, Tampa, FL, USA.
B Mark SmithersQueensland Melanoma Project, Princess Alexandra Hospital, University of Queensland, Brisbane, QLD, Australia.
Brendon J CoventryMelanoma Institute Australia, The University of Sydney, Sydney, NSW, Australia.
Douglas S TylerDepartment of Surgery, University of Texas Medical Branch, Galveston, TX, USA.
John F ThompsonMelanoma Institute Australia, The University of Sydney, Sydney, NSW, Australia.
Jonathan S ZagerDepartment of Cutaneous Oncology, Moffitt Cancer Center and Research Institute, Tampa, FL, USA. Jonathan.Zager@moffitt.org.ORCID http://orcid.org/0000-0002-6886-4468
Moffitt Cancer Center · USUniversity of South Florida · USDuke University · USThe University of Sydney · AUEmory University · USThe University of Melbourne · AUFox Chase Cancer Center · USHospital of the University of Pennsylvania · USRoyal Adelaide Hospital · AUThe Alfred Hospital · AUThe University of Queensland · AUThe University of Texas Medical Branch at Galveston · US

Funding

TRANSLATIONAL RESEARCHP30CA076292 · NCI · UNIVERSITY OF SOUTH FLORIDA · PI KENNETH Lynn WRIGHT · 1998 to 2026
$93.5M
PVSRIPO in melanomaK08CA237726 · NCI · DUKE UNIVERSITY · PI BEASLEY, GEORGIA · 2020 to 2024
$1.0M
NCI NIH HHS K08 CA237726NCI NIH HHS P30 CA076292
6 · The paper itself

Abstract

backgroundIsolated limb infusion (ILI) is a minimally invasive procedure for delivering high-dose chemotherapy to extremities affected by locally advanced or in-transit melanoma. This study compared the outcomes of melanoma patients treated with ILI in the United States of America (USA) and Australia (AUS).

methodsPatients with locally recurrent in-transit melanoma treated with ILI at USA or AUS centers between 1992 and 2018 were identified. Demographic and clinicopathologic characteristics were collected. Primary outcomes of treatment response, in-field progression-free survival (IPFS), distant progression-free survival (DPFS), and overall survival (OS) were evaluated by the Kaplan-Meier method. Multivariable analysis evaluated whether availability of new systemic therapies affected outcomes.

resultsMore ILIs were performed in AUS (n = 411, 60 %) than in the USA (n = 276, 40 %). In AUS, more ILIs were performed for stage 3B disease than in the USA (62 % vs 46 %; p < 0.001). The reported complete response rates were similar (AUS 30 % vs USA 29 %). Among the stage 3B patients, AUS patients had better IPFS (p = 0.001), whereas DPFS and OS were similar between the two countries. Among the stage 3C patients, the USA patients had better OS (p < 0.001), whereas IPFS and DPFS were similar. Availability of new systemic therapies did not affect IPFS or DPFS in either country. However, the USA patients who received ILI after ipilimumab approval in 2011 had significantly improved OS (hazard ratio, 0.62; p = 0.013).

conclusionsAUS patients were treated at an earlier disease stage than the USA patients with better IPFS for stage 3B disease. The USA patients treated after the availability of new systemic therapies had a better OS.

Indexed as

MelanomaSkin NeoplasmsAntineoplastic Combined Chemotherapy ProtocolsAustraliaChemotherapy, Cancer, Regional PerfusionExtremitiesFemaleHumansMaleMelphalanUnited StatesMelphalan

Identifiers

PMID32918177
PMCPMC7674259
OpenAlexW3084989042

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.